SLC5A2 and obesity disorder: Certain anti-obesity and diabetes drugs, particularly glucagon-like peptide-1 (GLP-1) receptor agonists and sodium glucose cotransporter 2 (SGLT2) inhibitors, have proven effective in managing diabetes in liver transplant recipients.